陳誠(chéng) 唐成武
[摘要] 目的 探討加速康復(fù)外科措施對(duì)結(jié)腸癌患者術(shù)后免疫功能的影響。 方法 2013年5月~2016年6月間76例結(jié)腸癌患者在本院行手術(shù)治療,其中37例患者接受加速康復(fù)外科治療(ERAS組),其余 39患者接受常規(guī)治療(對(duì)照組)。比較兩組患者術(shù)后免疫功能。 結(jié)果 ERAS組術(shù)后CD4+%(26.68±2.01 vs 25.54±1.77,P=0.0105)、CD4+/CD8+(0.95±0.12 vs 0.88±0.11,P=0.0098)明顯高于對(duì)照組;而CD8+%明顯低于對(duì)照組(27.25±1.72 vs 28.29±1.89,P=0.0152)。ERAS組術(shù)后IgA水平(2.59±0.27 vs 2.12±0.28, P=0.0000);IgM水平(1.64±0.13 vs 1.24±0.11,P=0.0000)、IgG水平(11.17±1.27 vs 8.01±1.01,P=0.0000)明顯高于對(duì)照組。 結(jié)論 加速康復(fù)外科措施能促進(jìn)結(jié)腸癌患者術(shù)后免疫功能的恢復(fù),提高術(shù)后免疫功能。
[關(guān)鍵詞] 結(jié)腸癌;加速康復(fù)外科;細(xì)胞免疫;體液免疫;免疫功能
[中圖分類號(hào)] R735.3 [文獻(xiàn)標(biāo)識(shí)碼] B [文章編號(hào)] 1673-9701(2018)19-0044-03
Effect of accelerated rehabilitation surgery on postoperative immune function in the patients with colon cancer
CHEN Cheng TAO Chengwu
Department of Surgery, the First Peoples Hospital of Huzhou University, Huzhou 313000, China
[Abstract] Objective To investigate the effects of accelerated rehabilitation measures on postoperative immune function in the patients with colon cancer. Methods From May 2013 to June 2016, 76 patients with colon cancer who were given surgery in our hospital were selected. Among them, 37 patients underwent accelerated rehabilitation surgery(ERAS group), and the remaining 39 patients received routine treatment(control group). Postoperative immune function was compared between the two groups. Results CD4+% in the ERAS group was(26.68±2.01 vs 25.54±1.77, P= 0.0105) after surgery, CD4+/CD8+(0.95±0.12 vs 0.88±0.11, P=0.0098) was significantly higher than that in the control group; while CD8+% was significantly lower than that in the control group(27.25±1.72 vs. 28.29±1.89, P=0.0152). The level of IgA in the ERAS group was (2.59±0.27 vs. 2.12±0.28, P=0.0000) after the surgery. IgM level was(1.64±0.13 vs. 1.24±0.11, P=0.0000), IgG level was(11.17±1.27 vs. 8.01±1.01, P=0.0000), significantly higher than that in the control group. Conclusion Accelerated rehabilitation measures can promote the recovery of postoperative immune function and improve the postoperative immune function in the patients with colon cancer.
[Key words] Colon cancer; Accelerated rehabilitation surgery; Cellular immunity; Humoral immunity; Immune function
結(jié)腸癌是我國(guó)常見的消化道惡性腫瘤,發(fā)病率居我國(guó)惡性腫瘤的第四位,并有逐漸上升的趨勢(shì)[1]。
目前針對(duì)結(jié)腸癌最有效的治療手段是根治切除。結(jié)腸腫瘤傳統(tǒng)的圍術(shù)期處理方法患者常較痛苦,患者承受的生理及心理的創(chuàng)傷應(yīng)激巨大,導(dǎo)致患者免疫功能下降明顯,使術(shù)后恢復(fù)時(shí)間延長(zhǎng)。
加速康復(fù)外科(enhanced recovery after surgery,ERAS)指通過(guò)各種手術(shù)前后的準(zhǔn)備措施,來(lái)降低手術(shù)引起的創(chuàng)傷及應(yīng)繳反應(yīng),促進(jìn)患者恢復(fù),在臨床實(shí)踐中被到越來(lái)越多的應(yīng)用。本研究將ERAS應(yīng)用于結(jié)腸癌手術(shù)患者,探討其對(duì)免疫功能的影響,現(xiàn)報(bào)道如下。
1 資料與方法
1.1 一般資料
回顧性研究 2013年5月~2016年6月間在本院行手術(shù)治療的76例結(jié)腸癌患者,納入標(biāo)準(zhǔn):年齡75歲以下;無(wú)全身轉(zhuǎn)移;無(wú)手術(shù)禁忌證;無(wú)血液免疫系統(tǒng)疾?。缓炇鹬委熤橥鈺?。76例患者隨機(jī)分為兩組,兩組患者的一般資料無(wú)顯著統(tǒng)計(jì)學(xué)意義(P>0.05)(表1)。
1.2 ERAS處理措施
加速康復(fù)組采用ERAS措施處理,對(duì)照組采用常規(guī)措施處理。見表2。
1.3 觀察指標(biāo)
兩組患者在術(shù)前及術(shù)后第7天檢測(cè)患者細(xì)胞免疫及體液免疫功能。細(xì)胞免疫功能包括:CD4+T細(xì)胞比例、CD8+T細(xì)胞比例及CD4+/CD8+比值,采用流式細(xì)胞儀檢測(cè)。體液免疫包括IgA、IgM和IgG水平,采用散射比濁法進(jìn)行測(cè)定。
1.4統(tǒng)計(jì)學(xué)方法
采用統(tǒng)計(jì)軟件SPSS 21.0進(jìn)行統(tǒng)計(jì)分析,計(jì)量資料以均數(shù)±標(biāo)準(zhǔn)差(x±s)表示,采用t檢驗(yàn);計(jì)數(shù)資料采用χ2檢驗(yàn)。P<0.05表示差異有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2.1 兩組患者細(xì)胞免疫功能的比較
術(shù)前兩組CD4+、CD8+和CD4+/CD8+無(wú)明顯差異,ERAS組術(shù)后CD4+ 明顯高于對(duì)照組(26.68±2.01 vs 25.54±1.77,P=0.0105);ERAS組術(shù)后CD8+明顯低于對(duì)照組(27.25±1.72 vs 28.29±1.89,P=0.0152);ERAS組術(shù)后CD4+/CD8+明顯高于對(duì)照組(0.95±0.12 vs 0.88±0.11,P=0.0098)。見表3。
2.2 兩組患者體液免疫功能比較
術(shù)前兩組免疫球蛋白水平無(wú)明顯差異。ERAS組術(shù)后IgA水平明顯高于對(duì)照組(2.59±0.27 vs 2.12±0.28,P=0.0000);ERAS組術(shù)后IgM水平明顯高于對(duì)照組(1.64±0.13 vs 1.24±0.11,P=0.0000);ERAS組術(shù)后IgG水平明顯高于對(duì)照組(11.17±1.27 vs 8.01±1.01,P=0.0000)。見表4。
3討論
結(jié)腸癌在全球范圍內(nèi)發(fā)病率逐年升高,全球每年大約有120萬(wàn)新發(fā)病例,有超過(guò)60萬(wàn)例患者死于結(jié)腸癌[2,3]。在我國(guó),結(jié)腸癌發(fā)病率同樣出現(xiàn)上升趨勢(shì)。結(jié)腸癌早期可無(wú)特異性表現(xiàn),給早期診斷帶來(lái)困難。手術(shù)切除是公認(rèn)的根治結(jié)腸癌最直接的治療方法。但是手術(shù)創(chuàng)傷巨大,并激活各種炎癥通道從而引起應(yīng)激反應(yīng),導(dǎo)致體內(nèi)免疫功能紊亂[4,5]。而免疫功能受損使機(jī)體對(duì)感染和腫瘤的防御能力下降,使得患者生活質(zhì)量進(jìn)一步下降[6,7]。因此需要在圍手術(shù)期采取積極措施及準(zhǔn)備,以減少患者應(yīng)激反應(yīng),最大限度減少對(duì)免疫系統(tǒng)的干擾,促進(jìn)患者快速康復(fù)。
ERAS理念是本世紀(jì)初出現(xiàn)的以減少術(shù)后應(yīng)激,促進(jìn)患者康復(fù)為目的的包括術(shù)前、術(shù)中及術(shù)后的一系列干預(yù)措施[8-10]。ERAS理念改變了很多常規(guī)圍手術(shù)期的流程,如術(shù)前2~3 h飲葡萄糖溶液,不常規(guī)清潔腸道[11,12],術(shù)后早期恢復(fù)飲食、早期下床等[13]。通過(guò)一系列大樣本隨機(jī)對(duì)照研究,ERAS被證實(shí)能很大程度減少手術(shù)應(yīng)激,加快患者康復(fù),提高術(shù)后生活質(zhì)量及免疫功能的恢復(fù)。ERAS理念已被廣泛接受及應(yīng)用,并在2015年被納入中國(guó)結(jié)直腸手術(shù)專家共識(shí)[14,15]。
大量研究發(fā)現(xiàn)機(jī)體免疫功能與腫瘤的發(fā)生及進(jìn)展有著密不可分的關(guān)系??赡芤?yàn)榘┘?xì)胞能分泌免疫抑制因子導(dǎo)致免疫球蛋白水平降低及CD4+、CD8+ T細(xì)胞數(shù)量及比例失衡,造成機(jī)體對(duì)腫瘤細(xì)胞抵抗力下降[16,17]。免疫球蛋白(Ig)是體液免疫效應(yīng)分子,可分為IgG、IgA、IgM等。在腫瘤患者體內(nèi)Ig水平往往低于健康人群,可能暗示體液免疫功能與腫瘤發(fā)生有密切關(guān)系[18]。CD4+ T細(xì)胞和CD8+ T細(xì)胞是體內(nèi)主要的細(xì)胞免疫組成部分。當(dāng)體內(nèi)CD4+ T細(xì)胞比例增高時(shí),表明機(jī)體免疫力增強(qiáng),能迅速應(yīng)對(duì)外界致病因子,并產(chǎn)生免疫反應(yīng)清除致病原。而當(dāng)CD8+ T細(xì)胞比例升高,表明機(jī)體的免疫功能處于抑制狀態(tài)。CD4+/CD8+細(xì)胞比例失衡被認(rèn)為是自身免疫性疾病、惡性腫瘤等多種疾病的原因[19,20]。
有研究認(rèn)為通過(guò)加速康復(fù)方法的優(yōu)化,可以改善患者術(shù)后的應(yīng)激狀態(tài),減少蛋白質(zhì)的流失以及炎癥反應(yīng)的發(fā)生,進(jìn)而使患者能維持較好的免疫功能,有利于維持患者的長(zhǎng)期生存[21]。本研究發(fā)現(xiàn),ERAS組術(shù)后IgA、IgG、IgM水平、CD4+ T細(xì)胞比率及CD4+/CD8+均高于對(duì)照組,而CD8+T細(xì)胞比率低于對(duì)照組,表明ERAS措施能使患者從手術(shù)創(chuàng)傷中快速康復(fù),達(dá)到重建免疫機(jī)制、增強(qiáng)患者免疫功能,增強(qiáng)機(jī)體抗腫瘤能力。
[參考文獻(xiàn)]
[1] Li M,Wang S,Han X,et al. Cancer mortality trends in an industrial district of Shanghai,China,from 1974 to 2014,and projections to 2029[J].Oncotarget,2017,8(54): 92470-92482.
[2] 張玥,石菊芳,黃慧瑤,等.中國(guó)人群結(jié)直腸癌疾病負(fù)擔(dān)分析[J].中華流行病學(xué)雜志,2015,(7):709-714.
[3] 龔楊明,吳春曉,張敏璐,等.上海人群結(jié)直腸癌生存率分析[J].中國(guó)癌癥雜志,2015,(7):497-504.
[4] 王亞儒,唐孝良,陳永樂,等.不同手術(shù)方式對(duì)結(jié)腸癌患者療效及免疫功能的影響[J].實(shí)用癌癥雜志,2016,31(9):1423-1425.
[5] 郭宏斌,劉超.腹腔鏡與開腹手術(shù)治療直腸癌的臨床療效及對(duì)免疫功能的影響[J].實(shí)用臨床醫(yī)藥雜志,2016, 20(1):65-68.
[6] 王光大,武中林,趙陽(yáng),等.免疫功能與食管鱗癌發(fā)生發(fā)展的關(guān)系研究[J].河北醫(yī)藥,2015,(24):3775-3776.
[7] 金志良,徐炎華.中西醫(yī)結(jié)合聯(lián)合化療對(duì)晚期結(jié)腸癌患者免疫功能及生活質(zhì)量的影響[J].湖北中醫(yī)藥大學(xué)學(xué)報(bào),2016,18(2):25-28.
[8] Jones D,Musselman R,Pearsall E,et al. Ready to Go Home? Patients' Experiences of the Discharge Process in an Enhanced Recovery After Surgery(ERAS)Program for Colorectal Surgery[J].Journal of Gastrointestinal Surgery,2017,21(11):1865-1878.
[9] Nimmo SM,F(xiàn)oo ITH,Paterson HM. Enhanced recovery after surgery:Pain management[J].Journal of Surgical Oncology,2017,116(5):583-591.
[10] Kagedan DJ,Devitt KS,Tremblay St-Germain A,et al.The economics of recovery after pancreatic surgery:Detailed cost minimization analysis of an enhanced recovery program[J].HPB,2017,19(11):1026-1033.
[11] Bray MS,Appel AL,Kallies KJ,et al.Implementation of an Enhanced Recovery After Surgery Program for Colorectal Surgery at a Community Teaching Hospital[J]. WMJ,2017,116(1):22-26.
[12] Oliveira RA,Guatura G,Peniche ACG,et al.An Integrative Review of Postoperative Accelerated Recovery Protocols[J].AORN Journal,2017,106(4):324-330 e325.
[13] Vendler MMI,Haidari TA,Waage JE,et al.Incidence of venous thromboembolic events in enhanced recovery after surgery for colon cancer:A retrospective,population-based cohortstudy[J].Colorectal Disease,2017,19(11):0393-0401.
[14] 江志偉,李寧. 結(jié)直腸手術(shù)應(yīng)用加速康復(fù)外科中國(guó)專家共識(shí)(2015版)[J].中華胃腸外科雜志,2015,(8):785-787.
[15] 中華醫(yī)學(xué)會(huì)腸外腸內(nèi)營(yíng)養(yǎng)學(xué)分會(huì)加速康復(fù)外科協(xié)作組.結(jié)直腸手術(shù)應(yīng)用加速康復(fù)外科中國(guó)專家共識(shí)(2015版)[J].中華消化外科雜志,2015,14(8):606-608 .
[16] Fu Y,Li Y,Xu L,etal. Immunology repertoire study of pulmonary sarcoidosis T cells in CD4+,CD8+ PBMC and tissue[J].Oncotarget,2017,8(52):89515-89526.
[17] Wang K,Shen T,Siegal GP,et al. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple negative breast cancer[J].Human pathology,2017,pii:S0046-8177(17):30357-X.
[18] 林蘭英.結(jié)腸癌圍手術(shù)期實(shí)施加速康復(fù)外科護(hù)理的效果研究[J].中外醫(yī)學(xué)研究,2016,14(26):90-91.
[19] McBride JA,Striker R. Imbalance in the game of T cells:What can the CD4/CD8 T-cell ratio tell us about HIV and health?[J].PLo S Pathogens,2017,13(11):e1006624.
[20] Barinov A,Galgano A,Krenn G,et al. CD4/CD8/Dendritic cell complexes in the spleen:CD8+ T cells can directly bind CD4+ T cells and modulate their response[J]. PloS one,2017,12(7):e0180644.
[21] Mari G,Costanzi A,Crippa J,et al.Surgical stress reduction in elderly patients undergoing elective colorectal laparoscopic surgery within an ERAS protocol[J].Chirurgia (Bucur),2016,111(6):476-480.
(收稿日期:2018-03-27)